Table C2.
CD4 count at ART initiation at second observed count <350a (simulated data)
| Frequency of regular visits | CD4 frequency during month after first CD4 <350 | Consecutive? | % Start ART | Median count (IQR) |
|
|---|---|---|---|---|---|
| Observed CD4 | True CD4 | ||||
| Four monthly | Once | — | 62 | 278 (232–315) | 311 (270–354) |
| Twice | Yes | 62 | 278 (232–315) | 313 (273–355) | |
| No | 66 | 286 (243–320) | 331 (290–371) | ||
| Four times | Yes | 65 | 284 (241–318) | 325 (287–363) | |
| No | 68 | 291 (250–323) | 345 (304–386) | ||
| Three monthly | Once | — | 63 | 282 (236–318) | 320 (281–362) |
| Twice | Yes | 64 | 283 (238–318) | 323 (283–364) | |
| No | 68 | 290 (248–322) | 340 (302–380) | ||
| Four times | Yes | 66 | 287 (245–321) | 334 (297–372) | |
| No | 70 | 295 (255–324) | 356 (317–395) | ||
CD4: CD4+ T lymphocyte; ART: antiretroviral treatment; IQR: interquartile range.
a
Occurring on average between 25 and 28 months from randomization in those initiating ART during follow-up (approximately two-thirds of participants).